Global Biosimilars Market Size, Share & Forecast 2026-2033

Overview

The global biosimilars market size was valued at USD 34.3 billion in 2025 and is projected to reach USD 94.4 billion by 2033, growing at a CAGR of 13.5% during the forecast period 2026-2033. Biosimilars are biological products that demonstrate high similarity to an already-approved reference biologic, with no clinically meaningful differences in safety, purity, or potency, and can be brought to market once the reference product's patent protection and regulatory exclusivity periods expire. Demand is rooted in the sheer cost gap between biosimilars and the reference biologics they compete with: biologic medicines account for a disproportionate share of global drug spending relative to the small patient populations they serve, and biosimilars typically enter national markets at list prices substantially below the originator product, creating an immediate, structural incentive for payers and health systems to support their adoption.

Regulatory momentum has accelerated sharply in the United States through 2025 and into 2026. The FDA announced new draft guidance in October 2025 reducing certain comparative efficacy study requirements, followed by additional draft guidance in March 2026 streamlining pharmacokinetic testing for biosimilar developers, changes the agency estimates could collectively save developers tens of millions of dollars and shave years off development timelines. North America accounted for an estimated 35% of global biosimilars revenue in 2025, the largest of any region, while Asia Pacific to expand at a CAGR of roughly 15% through 2033, the fastest pace of any region, as CDMO capacity build-outs and rising biosimilar adoption across China, Japan, and South Korea continue to narrow the gap with the more established Western markets.

Drivers

Rising Global Demand for Affordable Alternatives to Expensive Biologic Therapies

One of the most significant drivers of biosimilars market growth is the persistent, structural cost gap between biologic therapies and the biosimilars that compete with them once patent protection lapses. Biologic medicines, derived from living organisms rather than chemical synthesis, are among the most expensive therapies in modern medicine, and the rising global burden of chronic conditions including cancer, diabetes, and autoimmune disorders is steadily expanding the population of patients who require long-term biologic treatment that strains both individual and health-system budgets. Biopharmaceutical companies have responded by building out dedicated biosimilar development capability: Amgen has strategically focused on biosimilars drugs for infliximab and rituximab, Novartis has reorganized its structure around a dedicated biosimilars R&D division, and Roche has launched a subcutaneous formulation of Herceptin specifically to improve administration convenience, illustrating how biosimilar competition is reshaping strategy even among companies that also sell originator biologics.

Increasing Biosimilar Launches and Approvals Are Compounding Market Access

The steady increase in the number of biosimilar products approved and launched across major regulated markets is compounding overall market access, as each new approval both directly expands category revenue and demonstrates regulatory and commercial viability for the next wave of biosimilar developers. The FDA had approved 86 biosimilars as of May 2026, with the most recent approvals reaching into therapeutic categories, including oncology checkpoint inhibitors and long-acting insulins, that were once considered out of reach for biosimilar developers, while interchangeable designations, which allow pharmacist-level substitution without prescriber intervention in many U.S. states, are becoming increasingly common rather than the exception they once were.

Restraint

Manufacturing Complexity and High Development Costs Restrain Market Entry

The development of biosimilars is a significantly more intricate and resource-intensive process than developing a traditional small-molecule generic, representing a meaningful restraint on how quickly new entrants and new molecules can reach this market. Biosimilar manufacturers must replicate the complex structure and function of reference biologics derived from living organisms, a task that demands substantial investment in advanced bioprocessing infrastructure and extensive clinical trials evaluating efficacy, safety, and immunogenic potential against the reference product. According to FDA Commissioner Marty Makary, bringing a biosimilar to market has historically taken five to eight years and cost between USD 100 million and USD 300 million, a financial and timeline burden that continues to restrict biosimilar development to well-capitalized companies even as regulatory streamlining efforts work to lower this barrier over time.

Intense Competition and Pricing Pressure Among Market Players Compresses Margins

Once a biosimilar category attracts multiple competing manufacturers, the resulting price competition can compress margins to a degree that limits the financial return available even to successful developers. A 2025 study by the Association for Accessible Medicines found that biosimilars typically enter the market at prices roughly 40% below their reference biologic, and once several biosimilars compete for the same reference product, sustained price erosion can follow, restraining the per-unit profitability that might otherwise be expected from a fast-growing therapeutic category and reinforcing the importance of manufacturing scale and operational efficiency as competitive differentiators.

Trends and Opportunities in Biosimilars Market

The Looming GLP-1 Patent Cliff Represents a Major Emerging Opportunity

The approaching patent expiry of blockbuster GLP-1 receptor agonists, including semaglutide and liraglutide, both developed by Novo Nordisk and together generating billions of dollars in annual sales, represents one of the single largest emerging opportunities in this market. Liraglutide's patent expired in May 2024, and semaglutide's patent is scheduled to lapse in China in 2026 and globally in 2031, a timeline that has already prompted Chinese biopharmaceutical companies, including Hangzhou Jiuyuan Gene Engineering, a subsidiary of Huadong Medicine, to advance semaglutide biosimilar candidates through clinical development in anticipation of the China patent cliff, positioning the company to potentially become the first domestic manufacturer to win regulatory approval once exclusivity lapses.

Pembrolizumab's Looming Exclusivity Loss Is Concentrating Developer Attention on a Single, Enormous Target

Pembrolizumab, marketed as Keytruda and currently the world's best-selling drug with annual global sales of USD 29.5 billion in 2024, is projected to lose U.S. patent protection in 2028, and the scale of that single molecule's revenue is concentrating an unusual amount of biosimilar developer attention years ahead of the actual exclusivity cliff. At least seven developers, including Samsung Bioepis, Sandoz, Celltrion, Bio-Thera Solutions, and Amgen, are pursuing pembrolizumab biosimilar candidates, with Formycon AG announcing in February 2026 that its candidate FYB206 had demonstrated pharmacokinetic equivalence with Keytruda in a Phase 1 study, using a streamlined development pathway agreed with the FDA that bypassed the need for a full Phase 3 trial.

Interchangeable Designations Are Becoming a Distinct Commercial Differentiator

Securing an interchangeable designation, rather than standard biosimilar approval alone, is emerging as a distinct commercial opportunity, since interchangeable products can be substituted at the pharmacy level without requiring the original prescriber's intervention in many U.S. states, a meaningfully faster path to patient uptake than standard biosimilar status. Biocon Biologics' July 2025 FDA approval of Kirsty as the first interchangeable insulin aspart biosimilar, and the May 2026 approval of Immgolis as the first interchangeable golimumab biosimilars, both illustrate how developers willing to invest in the additional studies required for interchangeability are positioning themselves to capture share more quickly than competitors holding standard biosimilar approval for the same reference product.

Segment Analysis

The global biosimilars industry is segmented based on drug class, indication, and region.

Monoclonal Antibodies Lead the Drug-Class Segment

Monoclonal antibodies market segment held the largest share of the drug-class in 2025, encompassing key biosimilar molecules including infliximab, rituximab, adalimumab, trastuzumab, pembrolizumab, dupilumab, ustekinumab, and risankizumab. These complex molecules, developed using recombinant DNA technology to target specific proteins or cells in the body, are used extensively across oncology, autoimmune disease, and infectious disease treatment, and biosimilar versions of widely used monoclonal antibodies have steadily gained regulatory approval across major markets, with rituximab, trastuzumab, and adalimumab biosimilars approved in Europe and bevacizumab and ranibizumab biosimilars approved in the United States.

Monoclonal antibodies are simultaneously the fastest-growing drug-class segment, propelled by the steady cadence of patent expiries affecting blockbuster biologics and by accelerating biosimilar approval activity across this category specifically. The breadth of indications addressed by monoclonal antibody biosimilars, spanning oncology, autoimmune disease, and ophthalmology, combined with an unusually deep late-stage development pipeline targeting molecules such as pembrolizumab ahead of its scheduled 2028 patent expiry, is sustaining this segment's growth lead over every other drug class covered in this report.

Regulatory expansion of indications is also accelerating growth in this segment. In June 2025, the U.S. Food and Drug Administration approved new additional indications for three rituximab biosimilars—Truxima (rituximab-abbs), Riabni (rituximab-arrx), and Ruxience (rituximab-pvvr)—for the treatment of adult patients with moderate-to-severe pemphigus vulgaris (PV). Expanding approved uses increases the addressable patient population and strengthens market penetration for these biosimilars, reinforcing confidence among prescribers and payers.

On March 11, 2026, Celltrion announced the European launch of its Remsima IV liquid formulation, completing its portfolio alongside subcutaneous (SC) and IV powder formulations. Offering multiple delivery formats enhances flexibility for healthcare providers and patients, enabling use across hospital and outpatient settings while improving convenience and treatment adherence. By broadening formulation availability, companies can strengthen market penetration, differentiate their offerings within a competitive infliximab landscape, and support continued biosimilar adoption in both established and emerging markets.

Inflammatory & Autoimmune Diseases Leads the Indication Segment

Inflammatory & autoimmune diseases segment held a share of 35% in 2025. The segment is growing with a significant CAGR of 13.5% during the forecast period (2026-2033), because conditions such as Crohn’s disease, ulcerative colitis, plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis are chronic, progressively debilitating, and increasingly prevalent worldwide. These diseases often require long-term or lifelong biologic therapy to control inflammation, prevent disease progression, and improve quality of life. As patient populations expand and treatment durations lengthen, spending on biologics in immunology has risen substantially, creating strong pressure on healthcare systems to adopt more cost-effective alternatives.

Biosimilars help reduce overall treatment costs while maintaining comparable safety and efficacy, making them an attractive option for payers, providers, and patients. In February 2025, Biocon Biologics Ltd. launched Ustekinumab-kfce (YESINTEK) in the United States as a biosimilar to Stelara, indicated for Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. The entry of such biosimilars increases competition in high-value immunology markets, drives price reductions, and expands patient access to advanced therapies. As more blockbuster biologics used in autoimmune care lose exclusivity, additional biosimilar launches are expected to further strengthen growth in this segment.

Pricing and Reimbursement Landscape

Biosimilars compete primarily on price relative to their reference biologic, making reimbursement coding and payer-substitution policy as commercially important as clinical data once a biosimilar reaches the market.

Cumulative U.S. Savings Illustrate the Category's Real-World Economic Impact

Since the first U.S. biosimilar approval in 2015, the category has generated more than USD 56 billion in cumulative healthcare savings, according to Cardinal Health's 2026 Biosimilars Report, a figure that has accumulated even though biosimilars still account for only an estimated 23% of the U.S. biologics market where they compete, a level FDA Commissioner Marty Makary has characterized as falling short of the original policy goals behind the Biologics Price Competition and Innovation Act. Each individual biosimilar typically enters the market at a price roughly 40% below its reference biologic, and that single pricing dynamic, repeated across a growing number of approved molecules, is the primary mechanism behind the category's cumulative savings impact.

Rebate Walls and PBM Formulary Positioning Remain the Central U.S. Market-Access Battleground

Pharmacy benefit managers, rather than physicians or patients, function as the primary gatekeepers determining how quickly a biosimilar actually displaces its reference biologic in the United States, and the adalimumab (Humira) category remains the clearest illustration of how that gatekeeping power operates in practice. AbbVie's Humira retained an estimated 97% share of adalimumab prescription volume by the end of 2023, more than a year after the first biosimilars launched, a result widely attributed to AbbVie's use of rebate contracting, sometimes described as a "rebate wall," to keep its originator product preferentially positioned on PBM formularies despite the availability of lower list-priced alternatives. That dynamic began shifting only once the PBMs themselves found it more profitable to switch sides: CVS Caremark excluded branded Humira from its commercial formularies starting April 2024, and OptumRx followed in January 2025, steering patients instead toward biosimilars distributed through its own private-label biosimilar program, Nuvaila.

By 2025, 22 distinct adalimumab biosimilars were marketed in the United States at list prices ranging from 14% to 95% of Humira's reference price, yet most were themselves excluded from the major PBMs' standard 2025 formularies in favor of each PBM's own private-label biosimilar offering, illustrating how rebate economics, not list price alone, continue to determine which specific biosimilar actually reaches the patient. The Federal Trade Commission has separately filed an administrative complaint against the three largest PBMs, Caremark, Express Scripts, and OptumRx, along with their respective rebate-aggregator affiliates, alleging systematic preference for high-rebate products over lower-priced alternatives in a related drug category, a case that biosimilar manufacturers are watching closely given the structural similarity to adalimumab's own rebate dynamics.

National Tender Systems Shape Biosimilar Access Across European Hospital Markets

Most biosimilars administered in European hospital settings are procured through competitive tender processes rather than open-market pricing, with national or regional procurement bodies awarding fixed-term supply contracts to the winning bidder. Norway, which has run an annual tender system for hospital biologics since 2007, achieved a particularly striking outcome in 2015 when competitive tendering for infliximab secured the biosimilar Remsima at a price 72% below the reference product's official list price, a result frequently cited as evidence of tendering's savings potential when genuine multi-supplier competition exists.

Denmark, Norway, Portugal, and the United Kingdom operate centralized procurement agencies that manage some or all hospital biologic purchasing nationally, while most other European countries tender at the regional or individual hospital level; a 2026 position paper from Medicines for Europe found that member states still awarded more than half of all tenders on price alone, with relatively few contracting authorities incorporating supply-security or quality criteria into the award decision. That continued reliance on single-winner, price-only tender design has prompted growing policy concern over long-term market sustainability, since awarding an entire national or regional contract to a single lowest-price bidder can inadvertently push other biosimilar suppliers out of a market entirely, narrowing the supplier base the tender system was originally designed to keep competitive.

Manufacturing Capacity & Bioprocess Constraints

Unlike small-molecule generics, which can typically be manufactured by any facility with appropriate chemical synthesis capability, biosimilars depend on a much narrower set of specialized biologics manufacturing capacity, and that capacity constraint shapes which companies can realistically compete in this market regardless of their clinical or regulatory capability.

Cell Line Development Remains a Multi-Month Bottleneck Before Manufacturing Can Even Begin

Before a biosimilar can be manufactured at any scale, developers must first engineer and screen a stable, high-producing cell line capable of replicating the reference biologic's critical quality attributes, including its glycosylation pattern, charge variants, and bioactivity, without access to the originator's own proprietary cell line or process documentation. This reverse-engineering challenge, unique to biosimilar development relative to novel biologics, typically requires extensive clonal screening before a single candidate cell line is selected for scale-up, and any instability discovered later in development can force developers back to this earliest stage of the process, adding months or years to an already lengthy development timeline.

Bioreactor and Fill-Finish Capacity Remain Concentrated Among a Small Number of Global Suppliers

Large-scale biologics manufacturing requires bioreactor capacity that can hold up to 20,000 liters of cell culture media under tightly controlled temperature, pH, and dissolved-oxygen conditions, infrastructure that takes years and substantial capital to build and that remains concentrated among a relatively small number of global suppliers capable of operating at that scale. Sterile fill-finish, the step in which the purified biologic is filled into its final vial, syringe, or cartridge under aseptic conditions, represents a related and equally capital-intensive bottleneck; Sandoz's decision to build dedicated sterile fill-finish capacity as part of its broader Slovenia manufacturing investment, discussed in the Key Developments section of this report, reflects how even an established biosimilar leader continues to treat fill-finish capacity as a capability worth building rather than simply outsourcing in full.

CDMO Dependency Creates Both Strategic Flexibility and Single-Source Supply Risk

Most biosimilar developers, particularly smaller and mid-sized companies without their own large-scale biologics manufacturing infrastructure, rely on contract development and manufacturing organizations for some or all of the cell line development, drug substance manufacturing, and fill-finish steps required to bring a biosimilar to market, with leading CDMOs such as Samsung Biologics and WuXi Biologics having brought some of the largest-capacity biologics manufacturing facilities in the world online specifically to meet this demand. This model allows smaller developers to compete in this market without the capital burden of building their own manufacturing infrastructure, positioning CDMO capacity expansion, rather than originator-scale capital investment alone, as a viable second pathway for new entrants to reach commercial scale.

Geographical Penetration

North America Biosimilars Market: Deep Developer Bench and Accelerating Approvals Anchor Regional Leadership

North America held the leading regional share of the global biosimilars market in 2025, at an estimated 35% of global revenue, a position built on the sheer depth of its biosimilar developer base and a regulatory pathway that, despite years of slower-than-expected uptake, has matured into the most active biosimilar approval engine of any single national regulator.

Nearly every major global biosimilar developer, including Sandoz, Pfizer, Amgen, Celltrion, Biocon, and Fresenius Kabi, maintains a direct commercial presence in the United States biosimilars market, reflecting the sheer commercial value concentrated in a single national market large enough to support that level of competitive density. Favorable government initiatives supporting biopharma research and domestic manufacturing facility investment continue to drive growth across the Canada biosimilars market, the smaller of the two North American markets covered in this report.

Europe Biosimilars Market: Early Regulatory Leadership Sustains a Mature Second Position

Supportive regulatory frameworks, escalating R&D investment, and a rising prevalence of chronic disease continue to sustain the Europe biosimilars market as the second-largest regional market covered in this report, a position reinforced by the European Medicines Agency's status as the first major regulator to establish a dedicated biosimilar approval pathway well ahead of most other jurisdictions.

Acceptance of biosimilars by physicians over originator products continues to propel the Germany biosimilars market, the largest national market in the region, while a rising prevalence of life-threatening disease is fueling demand for low-priced alternatives across the UK biosimilars market. Increased government R&D investment is driving the France biosimilars market, favorable government regulation and reimbursement policy is propelling the Italy biosimilars market, and favorable patient incentives alongside high healthcare R&D expenditure are promoting biosimilar use across the Spain biosimilars market.

Asia Pacific Biosimilars Market: Fastest-Growing Region as CDMO Capacity and Domestic Demand Both Scale

The Asia Pacific biosimilars market is the fastest-growing region covered in this report, expanding at an estimated CAGR of approximately 15%, propelled by recent patent expiries of blockbuster reference products, government programs supporting domestic biotechnology manufacturing, and a build-out of regional contract development and manufacturing capacity that is increasingly competitive with established Western suppliers on both cost and scale.

High demand for affordable biologics combined with recent patent expiries of blockbuster biologics is driving the Japan biosimilars market, while increasing investment in pharmaceutical R&D and innovation continues to augment the China biosimilars market; Hangzhou Jiuyuan Gene Engineering's advanced clinical work on a semaglutide biosimilar ahead of the molecule's 2026 China patent expiry illustrates the scale of domestic biosimilar ambition in the country. The need to reduce government healthcare expenditure continues to propel adoption of biosimilars across the India biosimilars market, supported by national programs including the National Biopharma Mission that have strengthened the country's biotechnology manufacturing ecosystem, while favorable government incentives are promoting clinical biosimilar use across the South Korea biosimilars market and the launch of biosimilar-switching programs in healthcare settings is aiding adoption across the Australia biosimilars market.

South America Biosimilars Market: Brazil's Government Investment Anchors Regional Growth

Increased government pharmaceutical R&D investment continues to aid growth across the Brazil biosimilars market, the largest in the South America biosimilars market, while a well-developed regulatory landscape and high demand for chronic disease treatment are fueling biosimilar uptake across the Argentina biosimilars market. The rest of the region continues to expand from an earlier base as national regulatory frameworks for biosimilar approval continue to mature.

Middle East and Africa Biosimilars Market: Local R&D Investment and Rising Cancer Burden Drive a Developing Region

A focus on local pharmaceutical R&D continues to augment growth across the GCC Countries biosimilars market, part of the broader Middle East biosimilars market, while an increased cancer burden and the need for affordable alternatives to high-cost biologics continue to boost adoption across the Africa biosimilars market, both regions representing an earlier-stage but increasingly visible opportunity for global biosimilar manufacturers.

Key Developments

In May 2026, the FDA approved Immgolis and Immgolis Intri (golimumab-sldi), developed by Bio-Thera Solutions and commercialized in the U.S. by Accord BioPharma, as the first interchangeable biosimilars to Simponi and Simponi Aria for rheumatoid arthritis and ulcerative colitis.

In March 2026, the FDA issued new draft guidance recommending streamlined pharmacokinetic testing requirements for biosimilar developers, a change the agency estimates could reduce study costs by up to 50%, or approximately USD 20 million per program.

In July 2025, Sandoz announced the start of construction on a new biosimilars production center for sterile product manufacturing in Brnik, Slovenia, a USD 440 million project bringing the company's total planned investment in the country to more than USD 1.1 billion by 2029.

In July 2025, Biocon Biologics received FDA approval for Kirsty, the first and only interchangeable rapid-acting insulin aspart biosimilar in the United States.

In April 2025, Biocon Biologics received FDA approval for Jobevne (bevacizumab-nwgd), a biosimilar of bevacizumab for the intravenous treatment of several cancer types.

In April 2025, Biocon and Regeneron formed a license agreement to commercialize Yesafili (aflibercept-jbvf), an interchangeable biosimilar to aflibercept, in the United States.

In March 2025, Celltrion launched ZYMFENTRA (infliximab-dyyb) and STEQEYMA (ustekinumab-stba) in the U.S. market, biosimilars used to treat inflammatory bowel disease, plaque psoriasis, and psoriatic arthritis.